MCID: LYD001
MIFTS: 45

Leydig Cell Tumor

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Leydig Cell Tumor

MalaCards integrated aliases for Leydig Cell Tumor:

Name: Leydig Cell Tumor 12 54 43 15 17 71
Leydig Cell Tumor, Benign 71
Leydig Cell Neoplasm 12
Tumor, Leydig Cell 39

Classifications:



External Ids:

Disease Ontology 12 DOID:2696
MeSH 43 D007984
NCIt 49 C3188 C4213
SNOMED-CT 67 45002009 77870005
UMLS 71 C0023601 C0334409 C0334410

Summaries for Leydig Cell Tumor

Disease Ontology : 12 A sex cord-gonadal stromal tumor that secretes testosterone characterized by excessive proliferation of Leydig cells located in ovary or testicle.

MalaCards based summary : Leydig Cell Tumor, also known as leydig cell tumor, benign, is related to sertoli-leydig cell tumor and testicular leydig cell tumor. An important gene associated with Leydig Cell Tumor is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Bevacizumab and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, testis and testes, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Related Diseases for Leydig Cell Tumor

Diseases related to Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 304)
# Related Disease Score Top Affiliating Genes
1 sertoli-leydig cell tumor 34.2 SYP INSL3 INHA CYP17A1 CALB2 AFP
2 testicular leydig cell tumor 33.8 INSL3 GNAS CYP21A2
3 gynecomastia 30.8 INHA GNRH1 ESR1 CYP21A2 CYP19A1
4 estrogen excess 30.7 GNRH1 ESR1 CYP19A1
5 rete testis adenocarcinoma 30.6 CALB2 AFP
6 teratoma 30.6 SYP ESR1 CALB2 AFP
7 endometrial hyperplasia 30.5 ESR1 CYP19A1 CYP17A1
8 hydrocele 30.5 ESR1 CALB2 AFP
9 cystadenofibroma 30.4 INHA CALB2 AFP
10 myoma 30.3 GNRH1 ESR1 CYP19A1
11 amenorrhea 30.3 NR5A1 LHCGR GNRH1 CYP19A1 CYP17A1
12 bone resorption disease 30.3 PTHLH ESR1 CYP19A1
13 adrenogenital syndrome 30.3 SYP INHA HSD3BP4 CYP21A2
14 granulosa cell tumor of the ovary 30.3 SYP INHA
15 germ cell cancer 30.3 LHCGR ESR1 AFP
16 cystic teratoma 30.3 SYP CALB2 AFP
17 adrenal rest tumor 30.2 NR5A1 INSL3 CYP21A2
18 dysgerminoma 30.1 PTHLH INHA AFP
19 adenomyosis 30.1 GNRH1 ESR1 CYP19A1
20 adenoma 30.1 SYP LHCGR GNAS CYP21A2
21 leiomyomatosis 30.0 LHCGR GNRH1 ESR1 CALB2
22 anovulation 30.0 GNRH1 CYP21A2 CYP19A1
23 appendix adenocarcinoma 30.0 SYP GNAS
24 precocious puberty 30.0 LHCGR GNRH1 GNAS CYP21A2 CYP19A1
25 hyperandrogenism 30.0 INSL3 GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
26 infertility 29.9 NR5A1 LHCGR INSL3 INHA GNRH1 CYP19A1
27 hypogonadism 29.9 NR0B1 LHCGR GNRH1 CYP19A1
28 leiomyoma 29.8 GNRH1 ESR1 CYP19A1 CYP17A1
29 leiomyoma, uterine 29.8 GNRH1 ESR1 CYP19A1 CYP17A1
30 sertoli cell tumor 29.6 SYP NR5A1 INHA CYP19A1 CALB2 AFP
31 hyperprolactinemia 29.6 PTHLH GNRH1 GNAS
32 cystadenoma 29.6 SYP INHA GNAS CALB2 AFP
33 mccune-albright syndrome 29.6 PTHLH GNAS CYP19A1
34 ovarian serous cystadenocarcinoma 29.5 SYP GNAS ESR1 CALB2
35 peutz-jeghers syndrome 29.5 INHA GNAS CYP19A1
36 adrenal adenoma 29.4 GNAS CYP21A2 CYP17A1 CYP11A1
37 endometrial cancer 29.3 INHA GNRH1 ESR1 CYP19A1 CYP17A1 CALB2
38 ovarian sex-cord stromal tumor 29.3 NR5A1 GNAS CALB2
39 choriocarcinoma 29.2 INHA CYP19A1 CYP11A1
40 male infertility 29.2 NR5A1 INSL3 INHA GNRH1 ESR1 CYP21A2
41 sex cord-gonadal stromal tumor 29.0 NR5A1 INHA GNAS CALB2 AFP
42 precocious puberty, male-limited 28.9 LHCGR INHA GNRH1 GNAS CYP21A2 CYP19A1
43 polycystic ovary syndrome 28.9 STAR GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
44 hypogonadotropic hypogonadism 28.9 NR5A1 NR0B1 LHCGR INSL3 GNRH1 CYP19A1
45 adrenal cortical carcinoma 28.9 SYP NR5A1 CYP21A2 CYP17A1 CYP11A1 CALB2
46 adrenal cortical adenoma 28.9 SYP NR5A1 INHA CYP21A2 CYP17A1 CYP11A1
47 adrenocortical carcinoma, hereditary 28.8 STAR GNAS CYP17A1 CYP11A1
48 endometriosis 28.6 STAR NR5A1 GNRH1 ESR1 CYP19A1 CYP17A1
49 ovarian disease 28.5 STAR LHCGR GNRH1 ESR1 CYP19A1 CYP17A1
50 conn's syndrome 28.1 NR0B1 LHCGR GNRH1 GNAS CYP21A2 CYP17A1

Graphical network of the top 20 diseases related to Leydig Cell Tumor:



Diseases related to Leydig Cell Tumor

Symptoms & Phenotypes for Leydig Cell Tumor

MGI Mouse Phenotypes related to Leydig Cell Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.27 AFP CALB2 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 endocrine/exocrine gland MP:0005379 10.25 AFP CYP11A1 CYP19A1 ESR1 GNAS GNRH1
3 homeostasis/metabolism MP:0005376 10.18 AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNAS
4 hematopoietic system MP:0005397 10.1 CYP11A1 CYP19A1 CYP21A2 ESR1 GNAS GNRH1
5 liver/biliary system MP:0005370 9.97 AFP CYP11A1 CYP19A1 ESR1 GNAS GNRH1
6 normal MP:0002873 9.85 CALB2 CYP11A1 CYP19A1 ESR1 GNAS GNRH1
7 neoplasm MP:0002006 9.8 AFP ESR1 GNAS GNRH1 INHA NR0B1
8 reproductive system MP:0005389 9.77 AFP CYP11A1 CYP17A1 CYP19A1 ESR1 GNRH1
9 skeleton MP:0005390 9.28 CYP17A1 CYP19A1 ESR1 GNAS GNRH1 INHA

Drugs & Therapeutics for Leydig Cell Tumor

Drugs for Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
4
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
5
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
6
Etoposide Approved Phase 2 33419-42-0 36462
7
Ipilimumab Approved Phase 2 477202-00-9
8
nivolumab Approved Phase 2 946414-94-4
9 Mitogens Phase 2
10 Immunologic Factors Phase 2
11 Endothelial Growth Factors Phase 2
12 Immunoglobulins, Intravenous Phase 2
13 Angiogenesis Inhibitors Phase 2
14 Immunoglobulin G Phase 2
15 Albumin-Bound Paclitaxel Phase 2
16 Tubulin Modulators Phase 2
17 Antimitotic Agents Phase 2
18 Immunoglobulins Phase 2
19 Antibodies Phase 2
20 Antibodies, Monoclonal Phase 2
21 Antineoplastic Agents, Immunological Phase 2
22 Etoposide phosphate Phase 2
23 Anti-Bacterial Agents Phase 2
24 Antibiotics, Antitubercular Phase 2
25
Gemcitabine Approved Phase 1 95058-81-4 60750
26 Anti-Infective Agents Phase 1
27 Antiviral Agents Phase 1
28 Immunosuppressive Agents Phase 1
29 Antimetabolites Phase 1
30
Vincristine Approved, Investigational 57-22-7, 2068-78-2 5978
31
Doxorubicin Approved, Investigational 23214-92-8 31703
32
Dactinomycin Approved, Investigational 50-76-0 457193 2019
33
Ifosfamide Approved 3778-73-2 3690
34
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
35
Isophosphamide mustard 0
36
Liposomal doxorubicin 31703

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy Completed NCT00006227 Phase 2 Paclitaxel
2 A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
3 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Recruiting NCT01042522 Phase 2 Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
4 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
5 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
6 DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood Completed NCT01572467
7 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
8 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
9 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
10 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Leydig Cell Tumor

Cochrane evidence based reviews: leydig cell tumor

Genetic Tests for Leydig Cell Tumor

Anatomical Context for Leydig Cell Tumor

The Foundational Model of Anatomy Ontology organs/tissues related to Leydig Cell Tumor:

19
Ovary

MalaCards organs/tissues related to Leydig Cell Tumor:

40
Ovary, Testis, Testes, Breast, Lung, Endothelial, Bone

Publications for Leydig Cell Tumor

Articles related to Leydig Cell Tumor:

(show top 50) (show all 960)
# Title Authors PMID Year
1
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. 61 54
19679653 2009
2
Leydig cell tumor and malignant lymphoma in a patient with nonclassical 21-hydroxylase deficiency. 61 54
19367056 2009
3
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor. 61 54
17656605 2007
4
Possible mechanism for testicular focal necrosis induced by hCG in rats. 54 61
17077584 2006
5
Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. 61 54
15753388 2005
6
Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. 61 54
9253328 1997
7
Occurrence of FSH, inhibin and other hypothalamic-pituitary-intestinal hormones in normal fertility, subfertility, and tumors of human testes. 61 54
7749434 1995
8
Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. 61 54
8462465 1993
9
Extraadrenal expression of steroid 21-hydroxylase and 11 beta-hydroxylase by a benign testicular Leydig cell tumor. 61 54
1751389 1991
10
Leydig cell tumor estrogen secretion: suppression by a gonadotropin releasing hormone agonist. 54 61
1940064 1991
11
Measurement of circulating parathyroid hormone-related protein in rats with humoral hypercalcemia of malignancy using a two-site immunoradiometric assay. 54 61
2387260 1990
12
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line. 54 61
2340950 1990
13
Diagnosis of a small Leydig cell tumor by dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. 61
32382371 2020
14
[Ovarian Sertoli-Leydig cell tumors: DICER1 hotspot mutations and associated clinicopathological features]. 61
32392927 2020
15
Interstitial Leydig Cell Tumorigenesis-Leptin and Adiponectin Signaling in Relation to Aromatase Expression in the Human Testis. 61
32455738 2020
16
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. 61
31845841 2020
17
An update on the central nervous system manifestations of DICER1 syndrome. 61
30953130 2020
18
A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancer. 61
32565659 2020
19
An Excessive Testosterone Producing Testicular Leydig Cell Tumor as a Rare Cause of Secondary Acquired Erythrocytosis. 61
32289359 2020
20
Postmenopausal mild hirsutism and hyperandrogenemia due to ovarian Sertoli-Leydig cell tumor: A case report. 61
32280807 2020
21
Luteolin modulates gene expression related to steroidogenesis, apoptosis, and stress response in rat LC540 tumor Leydig cells. 61
31201582 2020
22
Management of Leydig cell tumors of the testis-a case report. 61
31754603 2020
23
Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. 61
31792767 2020
24
Ovarian tumors: a survey of selected advances of note during the life of this journal. 61
31654691 2020
25
Precocious Puberty Associated with Testicular Hormone-secreting Leydig Cell Tumor. 61
31893190 2019
26
Rare case of Leydig cell tumor with type I diabetes mellitus causing female pattern hair loss. 61
31456247 2019
27
Leydig cell tumorigenesis - implication of G-protein coupled membrane estrogen receptor, peroxisome proliferator-activated receptor and xenoestrogen exposure. In vivo and in vitro appraisal. 61
31759407 2019
28
Malignant leydig cell tumor in a 91-year-old man: Case report. 61
31808415 2019
29
Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian Origin (FATWO). 61
30134342 2019
30
Spontaneous Age-Related Histopathological Changes in Microminipigs. 61
31337280 2019
31
Imaging of DICER1 syndrome. 61
31620849 2019
32
Microscopic testicular sperm extraction or post-operative sperm reversal in functional Leydig cell tumor: case report. 61
31807432 2019
33
[Testicular tumors: A diagnostic challenge of imaging]. 61
31088679 2019
34
Ovarian Sertoli-Leydig Cell Tumor with Estrogenic Manifestations in a Postmenopausal Lady: a Case Report. 61
31496599 2019
35
Postmenopausal androgen-secreting ovarian tumors: challenging differential diagnosis in two cases. 61
30623686 2019
36
Fine needle aspiration diagnosis of metastatic Leydig cell tumor. Report of a case and review of the literature. 61
31272604 2019
37
Intraoperative Scrape Cytology from Ovarian Masss Lesions: A Study of 81 Cases. 61
31359919 2019
38
Malignant Leydig cell tumor in dogs: two cases and a review of the literature. 61
31248354 2019
39
WITHDRAWN: Metastatic Leydig Cell Tumor: A Clinico-pathological Review of Five Cases. 61
31307153 2019
40
Cyclooxygenase-2 is acutely induced by CCAAT/enhancer-binding protein β to produce prostaglandin E 2 and F 2α following gonadotropin stimulation in Leydig cells. 61
31087493 2019
41
Sertoli-Leydig cell tumor of the ovary: Analysis of a single institution database and review of the literature. 61
31106943 2019
42
Ovarian Sertoli-Leydig Cell Tumor With Heterologous Hepatocytes and a Hepatocellular Carcinomatous Element. 61
29620585 2019
43
Diagnosis of an indistinct Leydig cell tumor by positron emission tomography-computed tomography. 61
31139598 2019
44
Pleuropulmonary Blastoma: More Than a Lung Neoplasm of Childhood. 61
31527943 2019
45
Mesenteric extraovarian Sertoli-Leydig cell tumor without DICER1 hotspot mutation: a case report. 61
30935425 2019
46
Malignant Leydig Cell Tumor in Elderly Complete Androgen Insensitivity Patient: A Case Report. 61
31477948 2019
47
Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors. 61
30740951 2019
48
INSL3 Expression in Leydig Cell Hyperplasia and Leydig Cell Tumors. 61
29084059 2019
49
Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015. 61
30415435 2019
50
Leydig cell tumor in an Amur tiger (Panthera tigris altaica). 61
30541983 2019

Variations for Leydig Cell Tumor

Expression for Leydig Cell Tumor

Search GEO for disease gene expression data for Leydig Cell Tumor.

Pathways for Leydig Cell Tumor

GO Terms for Leydig Cell Tumor

Cellular components related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.8 CYP21A2 CYP19A1 CYP17A1

Biological processes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.84 PTHLH INSL3 INHA GNRH1
2 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.77 PTHLH LHCGR GNAS
3 female pregnancy GO:0007565 9.74 PTHLH GNRH1 GNAS
4 steroid hormone mediated signaling pathway GO:0043401 9.61 NR5A1 NR0B1 ESR1
5 uterus development GO:0060065 9.58 ESR1 CYP19A1
6 androgen metabolic process GO:0008209 9.58 ESR1 CYP19A1
7 intracellular receptor signaling pathway GO:0030522 9.58 NR5A1 NR0B1 ESR1
8 estrogen biosynthetic process GO:0006703 9.56 STAR CYP19A1
9 C21-steroid hormone biosynthetic process GO:0006700 9.55 STAR CYP11A1
10 progesterone metabolic process GO:0042448 9.52 CYP17A1 AFP
11 regulation of steroid biosynthetic process GO:0050810 9.51 STAR NR5A1
12 sterol metabolic process GO:0016125 9.5 CYP21A2 CYP19A1 CYP11A1
13 cellular response to gonadotropin stimulus GO:0071371 9.49 STAR LHCGR
14 sex determination GO:0007530 9.48 NR5A1 NR0B1
15 testosterone biosynthetic process GO:0061370 9.46 STAR CYP19A1
16 male sex determination GO:0030238 9.43 NR5A1 NR0B1 GNRH1
17 male gonad development GO:0008584 9.43 STAR NR5A1 NR0B1 LHCGR INHA ESR1
18 cellular response to luteinizing hormone stimulus GO:0071373 9.37 STAR LHCGR
19 glucocorticoid biosynthetic process GO:0006704 9.33 CYP21A2 CYP17A1 CYP11A1
20 steroid biosynthetic process GO:0006694 9.1 STAR NR0B1 CYP21A2 CYP19A1 CYP17A1 CYP11A1

Molecular functions related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.73 STAR NR5A1 ESR1 CYP21A2
2 heme binding GO:0020037 9.62 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 steroid hormone receptor activity GO:0003707 9.58 NR5A1 NR0B1 ESR1
4 iron ion binding GO:0005506 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 nuclear receptor activity GO:0004879 9.54 NR5A1 NR0B1 ESR1
6 hormone activity GO:0005179 9.46 PTHLH INSL3 INHA GNRH1
7 monooxygenase activity GO:0004497 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.92 CYP21A2 CYP19A1 CYP17A1 CYP11A1

Sources for Leydig Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....